Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 25, 2025
Finance
Sofinnova’s ‘pan-European’ play, China innovation and Trump’s tariff threat — a BioCentury podcast
How Biovelocita became the largest life sciences accelerator in Europe, the latest at FDA and more
BioCentury | Mar 25, 2025
Deals
Novo buys into obesity triple mechanism; AZ deepens China ties: Deals Report
Plus: Dren Bio strikes $600M bispecific agreement with Sanofi, and more
BioCentury | Mar 5, 2025
Data Byte
GLP-1 boom: no signs of slowing as sales continued to surge in 4Q24
Sales of top brands from both Lilly and Novo recorded all-time highs, again
BioCentury | Feb 18, 2025
Product Development
Remaking Roche
How the once-dominant cancer company has overhauled its strategy for long-term growth
BioCentury | Feb 12, 2025
Product Development
Promising early data for Tonghua Dongbao’s obesity program
BioCentury’s latest Clinical Report finds the obesity data came in a week when markets failed to reward readouts
BioCentury | Jan 31, 2025
Finance
Versant, Orbimed lead $65M launch of GIP-focused start-up Helicore
In BioCentury’s Venture Report: Oncomatryx, Quibin raise cash in Spain; Atalanta draws $97M; Forbion’s BioEconomy Fund
BioCentury | Jan 25, 2025
Product Development
Amylin is back with Novo’s positive amycretin data
Injectable amycretin shows 24% placebo-adjusted weight loss, giving it the lead in efficacy — at least for now
BioCentury | Nov 26, 2024
Product Development
Given dosing advantage, Amgen drug may not need best-in-class weight loss
Phase II MariTide data don’t differentiate on efficacy, but dosing schedule and supply could create commercial advantage
BioCentury | Nov 21, 2024
Finance
Versant-backed Pep2Tango taking four-way agonist to clinic for obesity
Program designed to reduce weight while sparing muscle mass, GI effects headed for IND next year
BioCentury | Nov 5, 2024
Product Development
Viking continues push for VK2735 as best in class in obesity
Dual GIP/GLP-1 agonist shows highly competitive efficacy, safety, dosing flexibility; although oral dose could limit commercial supply
Items per page:
1 - 10 of 42